Feature Channels:

Pharmaceuticals

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Drug Combination Shows Benefit in RAS-Driven Cancers

Dana-Farber Cancer Institute scientists report a number of patients in a small study with RAS-driven lung, ovarian, and thyroid cancers got long-term clinical benefit from a combination of two drugs that targeted molecular pathways controlled by the RAS gene.

Medicine

Channels:

ENDO 2017, Endocrine Society, Menopausal Hormone Therapy, Menopause, Bioidentical Hormones, Compounding, Hot Flash, Hot Flashes, Phase 3 clinical trial

New Natural Estrogen-Progesterone Capsule Reduces Postmenopausal Hot Flashes

A natural, or bioidentical, combined estradiol-progesterone capsule (TX-001HR) significantly decreases the frequency and severity of moderate to severe hot flashes in postmenopausal women, the Replenish study finds. Results of this phase 3, randomized, placebo-controlled, multicenter trial will be presented Monday at ENDO 2017, the Endocrine Society’s 99th annual meeting in Orlando, Fla.

Medicine

Channels:

Estetrol (E4), Prostate Cancer, Testosterone Levels, ENDO 2017, Endocrine Society, Endocrinology, Cancer, Men's Health, Prostate Cancer Treatment

Estetrol (E4) Shows Promise as a Safe, Effective Drug for Use in Advanced Prostate Cancer

The natural fetal estrogen estetrol, also called E4, is being tested as a new drug that may help treat advanced prostate cancer, according to an ongoing industry-sponsored study from the Netherlands. The final results will be presented in a poster on Saturday, April 1, at ENDO 2017, the annual scientific meeting of the Endocrine Society, in Orlando, Fla.

Medicine

Channels:

AACR, AACR 2017, Metformin, Statins, SEER database, Medicare, Pancreatic Cancer, New Jersey, Rutgers University, Diabetes, Cholesterol

Examination of Diabetes and Cholesterol Drugs in Pancreatic Cancer Mortality Shows Improved Survival with Use of One More Than the Other

Tan_XiangLin_2013_SH.jpg

Research has shown that by themselves, the diabetes drug metformin and cholesterol-lowering drugs known as statins are associated with reduced cancer mortality, but little is known about the effect on pancreatic cancer mortality when these drugs are taken together. Investigators at Rutgers Cancer Institute of New Jersey examined SEER Medicare data to further explore this approach and found that exposure to statins for these patients was significantly associated with reduced overall mortality.

Medicine

Channels:

Julie Brahmer, Cancer, Immunotherapy, drug, nivolumab, Lung Cancer, Johns Hopkins, Clinical Trial

Patients with Lung Cancers Responsive to Immunotherapy Drug Beat Standard Odds of Survival

More than seven years after the start of one of the first clinical trials of the immunotherapy drug nivolumab, researchers at the Johns Hopkins Kimmel Cancer Center report that the five-year survival estimate for a limited subset of people with advanced nonsmall cell lung cancer taking the drug is 16 percent, compared with a historical survival rate for that group of 1 to 4 percent.

Medicine

Life

Social and Behavioral Sciences

Channels:

Study Examines Public Understanding of Drug Rationing Amid AIDS Epidemic

A new study examines what young adults in Balaka, Malawi think about how anti-retroviral drugs are distributed amid an AIDS epidemic in the African nation.

Science

Channels:

Chemistry/Physics/Materials Sciences (Biochemistry, Pharmaceutical Sciences); Biology (Biochemistry); Medicine/Health (Neurobiology, Pharmaceutical Science)

Making a ‘Beeline’ Past the Blood-Brain Barrier for Drug Delivery

NM253BBB.jpg

Most medicines can’t get through the blood-brain barrier (BBB), a highly selective membrane that separates the circulatory system from the fluid bathing the brain. Certain peptides in animal venoms, however, can navigate across it to inflict damage. Now, researchers are capitalizing on venomous sneak attacks by developing a strategy based on a bee-venom peptide, apamin, to deliver medications to the brain.

Medicine

Channels:

MRSA, Superbugs, antibiotic resisistance

Case Western Reserve Embarks on Innovative Path to Treat Infections of Drug-Resistant Superbugs Such as MRSA Without Antibiotics

Case Western Reserve University and Q2 Pharma Ltd., an Israeli biopharmaceutical company, have signed a two-year option to license small molecule, antivirulence technology to potentially treat bacterial infections such as methicillin-resistant staphylococcus aureus (MRSA), the first known scientific effort of its kind.

Medicine

Science

Channels:

National Institutes of Health, computer-aided drug design, Public Health

University of Arkansas Chemist Receives $1.5 Million Award From the National Institutes of Health

FengWang.jpg

A new $1.5 million award from the National Institutes of Health will allow a University of Arkansas chemist to develop mathematical models to improve the reliability and efficiency of computer-aided drug design. The research could reduce the cost of drug discovery and lead to improvements in public health.

Medicine

Business

Channels:

Vision, Eye Cancer, light-activated AU-011, Aura Biosciences, ocular melanoma, Melanoma, Nanoparticle, Eyes, Clinical Trial, Ophthalmologist, Ophthalmology, Oncology

New Clinical Trial for Early-Stage Eye Melanoma Offers Study of Targeted Therapy

A first-of-its-kind, potentially groundbreaking new option for treating a form of eye cancer is now in its first phase-1 clinical research trial at Wills Eye Hospital in Philadelphia.







Chat now!